Abstract B085: Selective oral STK17A inhibitor UMF814A targets a previously unrecognized dark kinase vulnerability in spliceosome-mutant MDS and AML
Myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) remain therapeutically challenging, particularly in patients with spliceosome-mutant disease, where effective targeted options are lacking. Mutations in SF3B1, SRSF2, and U2AF1 define a biologically distinct subset associated with aberrant RNA splic...